
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2023-2030
Strong, semi-synthetic opioid oxycodone is prescribed by doctors to relieve moderate to severe pain. It is an extremely addictive substance that is frequently abused. It comes in formulations for immediate-release and controlled-release and is often taken by mouth. With the immediate-release formulation, the pain relief usually starts within fifteen minutes and lasts for up to six hours.
It can be administered intravenously in the United Kingdom. There are also combination products containing aspirin, ibuprofen, naloxone, and naltrexone. Euphoria, constipation, nausea, vomiting, lack of appetite, sleepiness, dizziness, itching, dry mouth, and sweating are typical side effects.
Addiction and dependence, substance misuse, agitation, depression or mania, psychosis, hallucinations, hypoventilation, gastroparesis, bradycardia, and hypotension are examples of severe adverse effects. Oxycodone may trigger allergies in people who are allergic to codeine. Early pregnancy oxycodone use seems to be generally safe. Rapidly stopping an opioid may result in withdrawal symptoms.
The -opioid receptor is activated by oxycodone. It has around 1.5 times the impact when consumed than a comparable amount of morphine does. The use of oxycodone is to treat moderate to severe pain. Oxycodone extended-release tablets and capsules are used to treat severe pain in patients who cannot be addressed with other medications and are anticipated to require pain medication 24 hours a day for a long time.
Pain that can be managed by medication taken as needed shouldn't be treated with oxycodone extended-release tablets or capsules. Only those who have taken opioid drugs for at least one week and are tolerant to them should be treated with oxycodone extended-release tablets, extended-release capsules, and concentrated solution.
The drug oxycodone belongs to the group of drugs known as opiate analgesics. It functions by altering how the nerve system and brain react to pain.
The Global Oxycodone Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
OxyContin was first launched, oxycodone HCL was designated for the treatment of chronic pain that is severe enough to call for the daily, round-the-clock opioid medication and for which no other available choices are effective.
Restrictions on Usage Reserve OxyContin for use in patients for whom alternative treatment options are ineffective, not tolerated, or would otherwise fall short to provide adequate pain management due to the risks of addiction, abuse, and misuse with opioids, even at the recommended doses, as well as the greater risks of overdose and death with extended-release opioid formulations.
The use of OxyContin as a temporary analgesic is not advised. Patients with Severe respiratory depression should not take OxyContin. Severe or severe bronchial asthma without resuscitation tools or in an unmonitored environment gastrointestinal blockage, including paralytic ileus, that is either known or suspected
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |